Lupin partners with Sino Universal for China expansion

Lupin (BSE: LUPIN) announced today a partnership with Sino Universal Pharmaceuticals (SUP) to launch Tiotropium Dry Powder Inhaler (DPI) in the Chinese market. The agreement grants SUP the responsibility for securing regulatory approvals, while Lupin will serve as the marketing authorization holder and oversee the manufacturing of the product. Tiotropium DPI, known for improving lung function in respiratory patients, aligns with Lupin's commitment to expanding healthcare solutions globally and reinforces their position in respiratory health. With 15 manufacturing sites and 7 global research centers, Lupin's expansion into China aims to meet the escalating healthcare needs of patients suffering from chronic obstructive pulmonary disease.